Krystal Biotech, Inc. KRYS Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

BridgeBio PharmaBBIO

$18.66M+84.3%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

BioCryst PharmaceuticalsBCRX

$12.52M+40.9%

Kyverna Therapeutics, Inc.KYTX

$8.72M—

FAQ

What is Krystal Biotech, Inc.'s operating lease liabilities (total)?

Krystal Biotech, Inc. (KRYS) reported operating lease liabilities (total) of $9.11M in Q1 2026.

How has Krystal Biotech, Inc.'s operating lease liabilities (total) changed year-over-year?

Krystal Biotech, Inc.'s operating lease liabilities (total) decreased by 5.7% year-over-year, from $9.66M to $9.11M.

What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities (total)?

Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities (total) has grown at a 18.8% compound annual growth rate (CAGR), from $3.95M to $9.34M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.